Draft Research Plan
Hearing Loss in Older Adults: Screening
November 08, 2018
Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
1. a. Does screening for hearing loss in asymptomatic adults age 50 years or older improve health outcomes?
b. Does the effectiveness of screening for hearing loss differ for subpopulations defined by age, sex, race/ethnicity, risk of past noise exposure, or comorbid condition?
2. What is the accuracy of primary care–relevant screening tests for hearing loss in adults age 50 years or older?
3. a. What are the harms of screening for hearing loss in adults age 50 years or older?
b. Do the harms of screening for hearing loss differ for subpopulations defined by age, sex, race/ethnicity, risk of past noise exposure, or comorbid condition?
4. a. How efficacious are interventions for screen-detected hearing loss in improving health outcomes in adults age 50 years or older?
b. Does the efficacy of interventions for screen-detected hearing loss differ for subpopulations defined by age, sex, race/ethnicity, risk of past noise exposure, or comorbid condition?
5. a. What are the harms of interventions for screen-detected hearing loss in adults age 50 years or older?
b. Do the harms of interventions for screen-detected hearing loss differ for subpopulations defined by age, sex, race/ethnicity, risk of past noise exposure, or comorbid condition?
Contextual questions will not be systematically reviewed and are not shown in the Analytic Framework.
- Does adherence to hearing aid use improve health outcomes in adults with screen-detected hearing loss who are prescribed hearing aids?
- Do interventions to improve hearing aid adherence improve health outcomes?
- In adults who are prescribed hearing aids, what are the potential barriers to obtaining hearing aids and reasons for low uptake?
The Proposed Research Approach identifies the study characteristics and criteria that the Evidence-based Practice Center will use to search for publications and to determine whether identified studies should be included or excluded from the Evidence Review. Criteria are overarching as well as specific to each of the key questions (KQs).
|Population||KQs 1–3: Adults age ≥50 years without diagnosed hearing loss, including those with comorbid depression, mild cognitive dysfunction, or diabetes
KQs 4, 5: Adults diagnosed with screen-detected (or recently detected) sensorineural hearing loss or presbycusis
|KQs 1–3: Adults age <50 years with previously diagnosed hearing loss; adults who currently use a hearing aid (within the past 6 months)
KQs 4, 5: Adults with conductive hearing loss, congenital hearing loss, sudden hearing loss, or hearing loss caused by recent noise
|Screening tests||KQs 1–3: Screening tests that are used, available, or feasible for use in primary care settings, including the whispered voice test, finger rub test, watch tick test, single-question screening regarding perceived hearing loss, hearing loss questionnaire, and screening audiometry (e.g., via handheld device)||KQs 1–3: Screening tests that are not used or available in primary care settings; Rinne and Weber tests (i.e., tests used to distinguish between sensorineural and conductive hearing loss)|
|Interventions||KQs 4, 5: Amplification with hearing aids or assistive listening devices, with or without additional education or counseling||KQs 4, 5: Nutritional pharmaceuticals, hearing rehabilitation, and cochlear implants|
|Outcomes||KQs 1, 4: Hearing-related quality of life and/or function (e.g., as measured by the Hearing Handicap Inventory for the Elderly), general health-related quality of life and/or function (e.g., as measured by the 36-Item Short-Form Health Survey), cognitive impairment, and depression
KQ 2: Sensitivity, specificity, positive and negative predictive value, positive and negative likelihood ratio, and diagnostic odds ratioKQs 3, 5: False-positive results, labeling, anxiety, and any other significant harms
|KQs 1, 4: Outcomes related to hearing aid performance and efficacy (e.g., speech intelligibility and quality of the listening experience)|
|Comparators||KQs 1, 3: Screened vs. nonscreened groups
KQ 2: Eligible screening tests vs. diagnostic pure-tone audiometry testingKQs 4, 5: Amplification vs. no intervention, wait-list control, or placebo amplification device
|All KQs: No comparison
KQs 4, 5: Studies comparing two different amplification devices
|Settings||All KQs: Studies performed in settings generalizable to primary care, including nursing home settings
KQs 2, 4, 5: Studies performed in specialty clinics
|Studies performed in occupational health settings|
|Countries||Studies conducted in countries categorized as “Very High” on the 2016 Human Development Index (as defined by the United Nations Development Programme)||Studies conducted in countries not categorized as “Very High” on the 2016 Human Development Index|
|Study designs||KQs 1, 4: Randomized, controlled trials and controlled cohort studies
KQ 2: Cross-sectional or cohort studiesKQs 3, 5: Randomized, controlled trials; controlled cohort studies; and case-control studies
|All other study designs*|
|Language||Full text published in English||Languages other than English|
|Study quality||Fair or good quality||Poor quality (according to design-specific USPSTF criteria)|
* Systematic reviews will be excluded from the evidence review. However, separate searches will be conducted to identify relevant systematic reviews, and the citations of all studies included in those systematic reviews will be reviewed to ensure that database searches capture all relevant primary studies.